Patents by Inventor Fabian Bert Scheifele

Fabian Bert Scheifele has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MAGE-A4 peptide dual T cell engagers
    Patent number: 12161673
    Abstract: Described herein are antigen binding proteins with specificity to Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC). Also described are multispecific antigen binding proteins comprising an antigen binding domain with specificity to CD3, and at least one MAGE-A4 pMHC antigen binding domain. Methods of treating cancer with the same are also described.
    Type: Grant
    Filed: September 13, 2023
    Date of Patent: December 10, 2024
    Assignee: CDR-LIFE AG
    Inventors: Stephanie Jungmichel, Fabian Bert Scheifele, Anna Maria Sobieraj, Philipp Robert Richle, Hannes Merten, Leonardo Borras, Christian Valdemar Vinge Leisner
  • MAGE-A4 PEPTIDE-MHC ANTIGEN BINDING PROTEINS
    Publication number: 20240279344
    Abstract: Antigen binding proteins that specifically recognize a target Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC), and nucleic acids encoding the same, are provided. Methods of producing antigen binding proteins that specifically recognize a target MAGE-A4 pMHC, and nucleic acid libraries encoding the same, are also provided.
    Type: Application
    Filed: January 4, 2024
    Publication date: August 22, 2024
    Inventors: Anna Maria Sobieraj, Fabian Bert Scheifele, Stephanie Jungmichel, Leonardo Borras, Christian Valdemar Vinge Leisner
  • MAGE-A4 peptide-MHC antigen binding proteins
    Patent number: 11912771
    Abstract: Antigen binding proteins that specifically recognize a target Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC), and nucleic acids encoding the same, are provided. Methods of producing antigen binding proteins that specifically recognize a target MAGE-A4 pMHC, and nucleic acid libraries encoding the same, are also provided.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: February 27, 2024
    Assignee: CDR-LIFE AG
    Inventors: Anna Maria Sobieraj, Fabian Bert Scheifele, Stephanie Jungmichel, Leonardo Borras, Christian Valdemar Vinge Leisner
  • MAGE-A4 PEPTIDE-MHC ANTIGEN BINDING PROTEINS
    Publication number: 20220380472
    Abstract: Antigen binding proteins that specifically recognize a target Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC), and nucleic acids encoding the same, are provided. Methods of producing antigen binding proteins that specifically recognize a target MAGE-A4 pMHC, and nucleic acid libraries encoding the same, are also provided.
    Type: Application
    Filed: March 9, 2022
    Publication date: December 1, 2022
    Inventors: Anna Maria Sobieraj, Fabian Bert Scheifele, Stephanie Jungmichel, Leonardo Borras, Christian Valdemar Vinge Leisner
  • RABBIT-DERIVED ANTIGEN BINDING PROTEIN NUCLEIC ACID LIBRARIES AND METHODS OF MAKING THE SAME
    Publication number: 20220340894
    Abstract: Rabbit antigen binding protein nucleic acid libraries are provided (e.g., nucleic acid libraries encoding antigen binding proteins that specifically recognize a target peptide-MHC (pMHC)). Methods of producing the rabbit antigen binding protein nucleic acid libraries are also provided.
    Type: Application
    Filed: March 9, 2022
    Publication date: October 27, 2022
    Inventors: Anna Maria Sobieraj, Severin Oliver Wendelspiess, Fabian Bert Scheifele